title: Clinical development of new drug-radiotherapy combinations.
abstract: In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures include the use of radiotherapy, either as a single modality or combined with other treatments. Radiotherapy can provide enormous benefit to patients with cancer. In the past decade, significant technical advances, such as image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy, and proton therapy enable higher doses of radiotherapy to be delivered to the tumour with significantly lower doses to normal surrounding tissues. However, apart from the combination of traditional cytotoxic chemotherapy with radiotherapy, little progress has been made in identifying and defining optimal targeted therapy and radiotherapy combinations to improve the efficacy of cancer treatment. The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) formed a Joint Working Group with representatives from academia, industry, patient groups and regulatory bodies to address this lack of progress and to publish recommendations for future clinical research. Herein, we highlight the Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer.
authors.affiliation: UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK.
authors.forename: Ricky A
authors.initials: RA
authors.lastname: Sharma
authors.affiliation: Newcastle University, Newcastle upon Tyne, UK.
authors.forename: Ruth
authors.initials: R
authors.lastname: Plummer
authors.affiliation: Cancer Research UK, London, UK.
authors.forename: Julie K
authors.initials: JK
authors.lastname: Stock
authors.affiliation: University of Oxford, Oxford, UK.
authors.forename: Tessa A
authors.initials: TA
authors.lastname: Greenhalgh
authors.affiliation: Eisai, Hatfield Business Park, UK.
authors.forename: Ozlem
authors.initials: O
authors.lastname: Ataman
authors.affiliation: Pfizer Ltd., Surrey, UK.
authors.forename: Stephen
authors.initials: S
authors.lastname: Kelly
authors.affiliation: Kinapse Ltd, London, UK.
authors.forename: Robert
authors.initials: R
authors.lastname: Clay
authors.affiliation: Cardiff University and Velindre Cancer Centre, Cardiff, UK.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Adams
authors.affiliation: University of Cambridge, Cambridge, UK.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Baird
authors.affiliation: University of Birmingham, Birmingham, UK.
authors.forename: Lucinda
authors.initials: L
authors.lastname: Billingham
authors.affiliation: University of Leeds, Leeds, UK.
authors.forename: Sarah R
authors.initials: SR
authors.lastname: Brown
authors.affiliation: Pfizer Ltd., Surrey, UK.
authors.forename: Sean
authors.initials: S
authors.lastname: Buckland
authors.affiliation: National Cancer Research Institute, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Bulbeck
authors.affiliation: University of Glasgow, Glasgow, UK.
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Chalmers
authors.affiliation: AstraZeneca, Cheshire, UK.
authors.forename: Glen
authors.initials: G
authors.lastname: Clack
authors.affiliation: MISSION Therapeutics Ltd, Cambridge, UK.
authors.forename: Aaron N
authors.initials: AN
authors.lastname: Cranston
authors.affiliation: Merck KGaA, Darmstadt, Germany.
authors.forename: Lars
authors.initials: L
authors.lastname: Damstrup
authors.affiliation: Astex Pharmaceuticals, Cambridge, UK.
authors.forename: Roberta
authors.initials: R
authors.lastname: Ferraldeschi
authors.affiliation: UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK.
authors.forename: Martin D
authors.initials: MD
authors.lastname: Forster
authors.affiliation: Vertex Pharmaceuticals (Europe) Ltd, Abingdon, UK.
authors.forename: Julian
authors.initials: J
authors.lastname: Golec
authors.affiliation: BTG International Ltd, London, UK.
authors.forename: Russell M
authors.initials: RM
authors.lastname: Hagan
authors.affiliation: The Institute of Cancer Research/The Royal Marsden NIHR Biomedical Research Centre, London, UK.
authors.forename: Emma
authors.initials: E
authors.lastname: Hall
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana, USA.
authors.forename: Axel-R
authors.initials: AR
authors.lastname: Hanauske
authors.affiliation: The Institute of Cancer Research/The Royal Marsden NIHR Biomedical Research Centre, London, UK.
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Harrington
authors.affiliation: National Cancer Research Institute, UK.
authors.forename: Tom
authors.initials: T
authors.lastname: Haswell
authors.affiliation: University of Oxford, Oxford, UK.
authors.forename: Maria A
authors.initials: MA
authors.lastname: Hawkins
authors.affiliation: University of Manchester, Manchester, UK.
authors.forename: Tim
authors.initials: T
authors.lastname: Illidge
authors.affiliation: Cancer Research UK, London, UK.
authors.forename: Hazel
authors.initials: H
authors.lastname: Jones
authors.affiliation: Sarah Cannon Research Institute, Nashville, Tennessee, USA.
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Kennedy
authors.affiliation: The Institute of Cancer Research/The Royal Marsden NIHR Biomedical Research Centre, London, UK.
authors.forename: Fiona
authors.initials: F
authors.lastname: McDonald
authors.affiliation: J&J Innovation, Menlo Park, California, USA.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Melcher
authors.affiliation: University of Manchester, Manchester, UK.
authors.forename: James P B
authors.initials: JP
authors.lastname: O'Connor
authors.affiliation: Vertex Pharmaceuticals (Europe) Ltd, Abingdon, UK.
authors.forename: John R
authors.initials: JR
authors.lastname: Pollard
authors.affiliation: University of Manchester, Manchester, UK.
authors.forename: Mark P
authors.initials: MP
authors.lastname: Saunders
authors.affiliation: University of Leeds, Leeds, UK.
authors.forename: David
authors.initials: D
authors.lastname: Sebag-Montefiore
authors.affiliation: Genentech Inc, South San Francisco, California, USA.
authors.forename: Melanie
authors.initials: M
authors.lastname: Smitt
authors.affiliation: Cardiff University and Velindre Cancer Centre, Cardiff, UK.
authors.forename: John
authors.initials: J
authors.lastname: Staffurth
authors.affiliation: University of Manchester, Manchester, UK.
authors.forename: Ian J
authors.initials: IJ
authors.lastname: Stratford
authors.affiliation: Newcastle University, Newcastle upon Tyne, UK.
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Wedge
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015687:Cell Hypoxia / Q000528:radiation effects; D002986:Clinical Trials as Topic / Q000379:methods; D003131:Combined Modality Therapy; D017277:Drug Approval; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D010353:Patient Education as Topic; D010358:Patient Participation; D011785:Quality Assurance, Health Care; D011787:Quality of Health Care; D011829:Radiation Dosage; D011836:Radiation Tolerance / Q000528:radiation effects; D016896:Treatment Outcome